Cited by 653Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 134 of the 144 references it cites were found in a registry or an index.

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, Jamil, Wu, Hsiao-Huei, Dasgupta, Gargi·2000·Gene

Open this paper in CoChat — free account

Abstract

MDM2 is an oncogene that mainly functions to modulate p53 tumor suppressor activity. In normal cells the MDM2 protein binds to the p53 protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome. Immediately after the application of cellular stress, the ability of MDM2 to bind to p53 is blocked or altered in a fashion that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. In this review, we present evidence for the existence of three highly conserved regions (CRs) shared by MDM2 proteins and MDMX proteins of different species. These highly conserved regions encompass residues 42-94 (CR1), 301-329 (CR2), and 444-483 (CR3) on human MDM2. These three domains are respectively important for binding p53, for binding the retinoblastoma protein, and for transferring ubiquitin to p53. This review discusses the major milestones uncovered in MDM2 research during the past 12 years and potential uses of this knowledge in the fight against cancer.

Integrity signals

Registry

Crossref · 10.1016/s0378-1119(99)00487-4

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation

Show all 144 references

Sorted by citations

Items 101–200 of 653

Discovery of a Nanomolar Inhibitor of the Human Murine Double Minute 2 (MDM2)−p53 Interaction through an Integrated, Virtual Database Screening Strategy
Lu, Y., Nikolovska‐Coleska, Z., Fang, X., Gao, W., Shangary, S. K., Qiu, S., Qin, D., & Wang, S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060023+ · Cited by 116
p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 117
Epstein-Barr Virus Nuclear Antigen 3C Augments Mdm2-Mediated p53 Ubiquitination and Degradation by Deubiquitinating Mdm2
Saha, A., Murakami, M., Kumar, P., Bajaj, B. G., Sims, K., & Robertson, E. S. (2009) · Journal of Virology · doi:10.1128/jvi.02408-08 · Cited by 120
The Fbw7 and BetaTRCP E3 ubiquitin ligases and their roles in tumorigenesis
Alan, W. L. (2012) · Frontiers in bioscience · doi:10.2741/4045 · Cited by 112
LncRNA Meg3 protects endothelial function by regulating the DNA damage response
Ali, M. S. S. H., Cheng, X., Moran, M., Haemmig, S., Naldrett, M. J., Alvarez, S., Feinberg, M. W., & Sun, X. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1190 · Cited by 113
Transcriptional Regulation of the mdm2 Oncogene by p53 Requires TRRAP Acetyltransferase Complexes
Ard, P. G., Chatterjee, C., Kunjibettu, S., Adside, L. R., Gralinski, L. E., & McMahon, S. B. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5650-5661.2002 · Cited by 113
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 111
Superoxide dismutase: an emerging target for cancer therapeutics
Hileman, E. O., Achanta, G., & Huang, P. (2001) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.5.6.697 · Cited by 101
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 104
p53 protein variants: structural and functional similarities with p63 and p73 isoforms
Courtois-Cox, S., de Fromentel, C. C., & Hainaut, P. L. (2004) · Oncogene · doi:10.1038/sj.onc.1206929 · Cited by 102
Evidence for a biphasic apoptotic pathway induced by melatonin in MCF‐7 breast cancer cells
Cucina, A., Proietti, S., D’Anselmi, F., Coluccia, P., Dinicola, S., Frati, L., & Bizzarri, M. (2009) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2008.00645.x · Cited by 101
How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures
Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 101
MDM2: life without p53
Daujat, S., NEEL, H., & PIETTE, J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02369-1 · Cited by 97
Fourier analysis and systems identification of the p53 feedback loop
Geva‐Zatorsky, N., Dekel, E., Batchelor, E., Lahav, G., & Alon, U. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001107107 · Cited by 96
Akt versus p53 in a Network of Oncogenes and Tumor Suppressor Genes Regulating Cell Survival and Death
Wee, K. B., & Aguda, B. D. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.077693 · Cited by 95
A Proteomics Analysis of Cell Signaling Alterations in Colorectal Cancer
Madoz‐Gúrpide, J., Cañamero, M., Sánchez, L., Solano, J., Alfonso, P., & Casal, J. I. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700006-mcp200 · Cited by 97
Melatonin down‐regulates MDM 2 gene expression and enhances p53 acetylation in MCF ‐7 cells
Proietti, S., Cucina, A., Dobrowolny, G., D’Anselmi, F., Dinicola, S., Masiello, M. G., Pasqualato, A., Palombo, A., Morini, V., Reiter, R. J., et al. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12150 · Cited by 99
MDM2 Amplified Sarcomas: A Literature Review
Sciot, R. (2021) · Diagnostics · doi:10.3390/diagnostics11030496 · Cited by 96
Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt–Mdm2–p53 pathway
Rogulski, K. R., Li, Y., Rothermund, K. D., Pu, L., Watkins, S. C., Yi, F., & Prochownik, E. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208897 · Cited by 96
Gene Expression Profiling of Low Selenium Status in the Mouse Intestine: Transcriptional Activation of Genes Linked to DNA Damage, Cell Cycle Control and Oxidative Stress
Rao, L., Prolla, T. A., & Puschner, B. (2001) · Journal of Nutrition · doi:10.1093/jn/131.12.3175 · Cited by 96
Unleashing the power of p53: lessons from mice and men: Figure 1.Preprint
Poyurovsky, M. V., & Prives, C. L. (2006) · Genes & Development · doi:10.1101/gad.1397506 · Cited by 96
MDM2 and MDMX can interact differently with ARF and members of the p53 family
Wang, X., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., & Poon, R. Y. C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02124-x · Cited by 94
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
RETRACTED ARTICLE: Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
Daniele, S., Costa, B., Zappelli, E., Pozzo, E. D., Sestito, S., Nesi, G., Campiglia, P., Marinelli, L., Novellino, E., Rapposelli, S., et al. (2015) · Scientific Reports · doi:10.1038/srep09956 · Cited by 94
Retracted
The Human MDM2 Oncoprotein Increases the Transcriptional Activity and the Protein Level of the p53 Homolog p63
Calabrò, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R., & Mantia, G. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107173200 · Cited by 94
Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
Gupta, A., Bharadwaj, M., Kumar, A., & Mehrotra, R. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-016-0089-0 · Cited by 95
Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export
Shinozaki, T., Nota, A., Taya, Y., & Okamoto, K. (2003) · Oncogene · doi:10.1038/sj.onc.1207176 · Cited by 93
A novel in vivo post‐translational modification of p53 by PARP‐1 in MPTP‐induced parkinsonism
Mandir, A. S., Simbulan-Rosenthal, C. M., Poitras, M. F., Lumpkin, J. R., Dawson, V. L., Smulson, M. E., & Dawson, T. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01144.x · Cited by 92
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 91
Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer
Kelley, M. L., Winge, P., Heaney, J. D., Stephens, R. E., Farrell, J. H., Beneden, R. J. V., Reinisch, C. L., Lesser, M. P., & Walker, C. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204144 · Cited by 89
Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression
Wang, C., Qi, R., Li, N., Wang, Z., An, H., Zhang, Q., Yu, Y., & Cao, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.002105 · Cited by 90
Retracted
Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis
Gupta, I., Singh, K., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00011 · Cited by 88
Novel targets of Akt, p21, and MDM2
Zhou, B. P., & Hung, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70128-0 · Cited by 88
Heterogeneity of hepatocellular carcinoma contributes to cancer progression
Jeng, K., Chang, C., Jeng, W., Sheen, I., & Jeng, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.009 · Cited by 87
An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors
Peng, T., Zhang, P., Liu, J., Nguyen, T. P. T., Bolshakov, S. V., Belousov, R., Young, E. D., Wang, X., Savannah, K. J. B., López-Terrada, D., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.185 · Cited by 87
Miniature Protein Inhibitors of the p53–hDM2 Interaction
Kritzer, J. A., Zutshi, R., Cheah, M. T., Ran, F. A., Webman, R. B., Wongjirad, T. M., & Schepartz, A. (2006) · ChemBioChem · doi:10.1002/cbic.200500324 · Cited by 90
Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer
Chen, D., Guo, Z., Yao, L., Sun, Y., Dian, Y., Zhao, D., Ke, Y., Zeng, F., Zhang, C., Deng, G., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103686 · Cited by 95
Oxidative stress induces p53‐mediated apoptosis in glia: p53 transcription‐independent way to die
Bonini, P., Cicconi, S., Cardinale, A., Vitale, C., Serafino, A., Ciotti, M. T., & Marlier, L. N. J. L. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10822 · Cited by 86
The RING domain of Mdm2 can inhibit cell proliferation.
Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., & Roussel, M. F. (2002) · PubMed · Cited by 86
Molecular pathogenesis of thyroid cancer
Segev, D. L., Umbricht, C. B., & Zeiger, M. A. (2003) · Surgical Oncology · doi:10.1016/s0960-7404(03)00037-9 · Cited by 87
Different Changes in Protein and Phosphoprotein Levels Result from Serum Starvation of High-Grade Glioma and Adenocarcinoma Cell Lines
Levin, V. A., Panchabhai, S. C., Shen, L., Kornblau, S. M., Qiu, Y., & Baggerly, K. A. (2010) · Journal of Proteome Research · doi:10.1021/pr900392b · Cited by 86
Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B
Wilder, P. T., Lin, J., Bair, C. L., Charpentier, T. H., Yang, D., Liriano, M. A., Varney, K. M., Lee, A., Oppenheim, A. B., Adhya, S. L., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.08.024 · Cited by 85
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Kim, K. W., Albert, J. M., Hallahan, D. E., & Lü, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 83
Senescence-Associated MicroRNAs
Munk, R. B., Panda, A. C., Grammatikakis, I., Gorospe, M., & Abdelmohsen, K. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.008 · Cited by 90
Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2
You, A., Nam, C.-W., Wakabayashi, N., Yamamoto, M. P., Kensler, T. W., & Kwak, M.-K. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.034 · Cited by 84
Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators
Gomez-Monterrey, I. M., Bertamino, A., Porta, A., Carotenuto, A., Musella, S., Aquino, C., Granata, I., Sala, M., Brancaccio, D., Picone, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100838z · Cited by 83
Physiological and Pathological Consequences of the Interactions of the p53 Tumor Suppressor with the Glucocorticoid, Androgen, and Estrogen Receptors
Sengupta, S., & Wasylyk, B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.005 · Cited by 82
Fish as model systems for the study of vertebrate apoptosis
Krumschnabel, G., & Podrabsky, J. E. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0281-y · Cited by 82
Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
Talib, W. H., Al-hadid, S. A., Ali, M. B. W., Al-Yasari, I. H., & Ali, M. R. A. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s167812 · Cited by 82
Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells
Elison, J. R. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.9.1269 · Cited by 81
Indole‐3‐carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells
Brew, C. T., Aronchik, I., Hsu, J. C., Sheen, J.-H., Dickson, R. B., Bjeldanes, L. F., & Firestone, G. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21445 · Cited by 79
Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
Aguilar, A., Sun, W., Liu, L., Lu, J., McEachern, D., Bernard, D., Deschamps, J. R., & Wang, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501541j · Cited by 79
Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes
Rajput, S., Puvvada, N., Kumar, B. N. P., Sarkar, S., Konar, S., Bharti, R., Dey, G., Mazumdar, A., Pathak, A., Fisher, P. B., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00692 · Cited by 80
The Two Upstream Open Reading Frames of Oncogene mdm2 Have Different Translational Regulatory Properties
Jin, X., Turcott, E., Englehardt, S., Mize, G. J., & Morris, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300316200 · Cited by 79
Ser326Cys polymorphism inhOGG1 gene and risk of esophageal cancer in a Chinese population
Xing, D.-Y., Tan, W., Song, N., & Lin, D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010520)95:3 · Cited by 153
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis
Ganguli, G., Abecassis, J., & Wasylyk, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.19.5135 · Cited by 78
Watching the watcher: Regulation of p53 by mitochondria
Holley, A. K., & St Clair, D. K. (2009) · Future Oncology · doi:10.2217/14796694.5.1.117 · Cited by 75
Molecular mechanisms of melatonin’s inhibitory actions on breast cancers
Proietti, S., Cucina, A., Reiter, R. J., & Bizzarri, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1161-8 · Cited by 75
Functional protein microarrays for parallel characterisation of p53 mutants
Boutell, J. M., Hart, D. J., Godber, B. L. J., Kozlowski, R. Z., & Blackburn, J. M. (2004) · PROTEOMICS · doi:10.1002/pmic.200300722 · Cited by 73
KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction
Okamoto, K., Kitabayashi, I., & Taya, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.022 · Cited by 74
Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 78
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Respiratory Syncytial Virus Decreases p53 Protein to Prolong Survival of Airway Epithelial Cells
Groskreutz, D. J., Monick, M. M., Yarovinsky, T. O., Powers, L. S., Quelle, D. E., Varga, S. M., Look, D. C., & Hunninghake, G. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2741 · Cited by 71
The emerging role of p53 in stem cells
Bonizzi, G., Cicalese, A., Insinga, A., & Pelicci, P. G. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.002 · Cited by 74
Functionalized Peptide-Based Nanoparticles for Targeted Cancer Nanotherapeutics: A State-of-the-Art Review
Sharma, R., Borah, S. J., Bhawna, Kumar, S., Gupta, A., Singh, P., Goel, V. K., Kumar, R., & Kumar, V. (2022) · ACS Omega · doi:10.1021/acsomega.2c03974 · Cited by 71
Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFalpha expression and caspase-2 activation
Yousfi, M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.4.359 · Cited by 71
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 72
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
MDM2 Is Required for Suppression of Apoptosis by Activated Akt1 in Salivary Acinar Cells
Limesand, K. H., Schwertfeger, K. L., & Anderson, S. M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01846-05 · Cited by 73
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination
Cheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69
p53 mediates the negative regulation of MDM2 by orphan receptor TR3
Zhao, B., Chen, H., Lei, N., Li, G., Zhao, W., Zhan, Y.-Y., Liu, B., Lin, S., & Wu, Q. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601435 · Cited by 69
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
He, S., Dong, G., Wu, S., Fang, K., Miao, Z., Wang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00664 · Cited by 68
Macrophages, Inflammation, and Tumor Suppressors: ARF, a New Player in the Game
Través, P. G., Luque, A., & Hortelano, S. (2012) · Mediators of Inflammation · doi:10.1155/2012/568783 · Cited by 71
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
Zhao, J., Lü, Y., & Shen, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.040 · Cited by 72
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration
Zhang, F., Tagen, M., Throm, S., Mallari, J., Miller, L., Guy, R. K., Dyer, M. A., Williams, R. T., Roussel, M. F., Nemeth, K., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035915 · Cited by 67
Discrimination for Genotoxic and Nongenotoxic Carcinogens by Gene Expression Profiling in Primary Mouse Hepatocytes Improves with Exposure Time
Mathijs, K., Brauers, K. J. J., Jennen, D. G. J., Boorsma, A., van Herwijnen, M. H. M., Gottschalk, R. W. H., Kleinjans, J. C. S., & van Delft, J. H. M. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp229 · Cited by 68
The Strength of Indecisiveness: Oscillatory Behavior for Better Cell Fate Determination
Lahav, G. (2004) · Science s STKE · doi:10.1126/stke.2642004pe55 · Cited by 67
Determinants of Specificity of MDM2 for the Activation Domains of p53 and p65: Proline27 Disrupts the MDM2-Binding Motif of p53
Zondlo, S. C., Lee, A. E., & Zondlo, N. J. (2006) · Biochemistry · doi:10.1021/bi060309g · Cited by 66
The ubiquitin-proteasome pathway in cell cycle control
Reed, S. I. (2006) · Springer eBooks · doi:10.1007/b136681 · Cited by 65
Biomarkers in Barrett Esophagus
Krishnadath, K. K., Reid, B. J., & Wang, K. K. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62394-x · Cited by 65
Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study
Kamaraj, B., & Bogaerts, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134638 · Cited by 62
Manganese superoxide dismutase vs. p53: Regulation of mitochondrial ROS
Holley, A. K., Dhar, S. K., & Clair, D. K. S. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.003 · Cited by 65
A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2
Berger, M., Sionov, R. V., Levine, A. J., & Haupt, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008879200 · Cited by 64
Molecular pathways in bladder cancer
Williams, S. G., & Stein, J. P. (2004) · Urological Research · doi:10.1007/s00240-003-0345-y · Cited by 63
C-terminal binding proteins: Emerging roles in cell survival and tumorigenesis
Bergman, L., & Blaydes, J. P. (2006) · APOPTOSIS · doi:10.1007/s10495-006-6651-4 · Cited by 62
The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development
Liu, G., Terzian, T., Xiong, S., Pelt, C. S. V., Audiffred, A., Box, N. F., & Lozano, G. (2007) · The Journal of Pathology · doi:10.1002/path.2238 · Cited by 62
Mdm2 in growth signaling and cancer
Levav-Cohen, Y., Haupt, S., & Haupt, Y. (2005) · Growth Factors · doi:10.1080/08977190500196218 · Cited by 60
Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species
Karawajew, L., Rhein, P., Czerwony, G., & Ludwig, W.-D. (2005) · Blood · doi:10.1182/blood-2004-09-3428 · Cited by 60
Binding of p53-derived Ligands to MDM2 Induces a Variety of Long Range Conformational Changes
Schön, O., Friedler, A., Freund, S. M. V., & Fersht, A. R. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.051 · Cited by 58
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
Small-Molecule MDM2-p53 Inhibitors: Recent Advances
Zhang, B., Golding, B. T., & Hardcastle, I. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.13 · Cited by 59
Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study
Nakayama, K., Kawano, Y., Kawakami, Y., Moriwaki, N., Sekijima, M., Otsuka, M., Yakabe, Y., Miyaura, H., Saito, K., Sumida, K., et al. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.09.008 · Cited by 57
MEK-ERK Signaling Controls Hdm2 Oncoprotein Expression by Regulating hdm2 mRNA Export to the Cytoplasm
Phelps, M., Phillips, A., Darley, M., & Blaydes, J. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412334200 · Cited by 57
A comprehensive study of p53 protein
Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 57
Regulation of p53 functions: let's meet at the nuclear bodies
Gostissa, M. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00038-3 · Cited by 56
C-Abl as a modulator of p53
Levav-Cohen, Y., Goldberg, Z., Zuckerman, V., Grossman, T., Haupt, S., & Haupt, Y. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.152 · Cited by 57
Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
Arif, T., Paul, A., Krelin, Y., Shteinfer‐Kuzmine, A., & Shoshan‐Barmatz, V. (2018) · Cancers · doi:10.3390/cancers10120499 · Cited by 57
Microcystin-LR induced DNA damage in human peripheral blood lymphocytes
Žegura, B., Gajski, G., Štraser, A., Garaj‐Vrhovac, V., & Filipič, M. (2011) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2011.10.002 · Cited by 54

Authors: Momand, J., Wu, H.-H., & Dasgupta, G.
Affiliations: California State University Los Angeles (US)
Corresponding author: Momand, Jamil
ORCID: Momand, Jamil
Wu, Hsiao-Huei
Venue: Gene
Publisher: Elsevier BV
Published: 2000-01
Volume: 242
Issue: 1-2
Pages: 15-29
ISSN: 0378-1119 (ISSN-L)
DOI: 10.1016/s0378-1119(99)00487-4
OpenAlex: W1973821009
Cited by: 641
References: 144
Citations by year: 2026: 6 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 24 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 22 · 2017: 14 · 2016: 17 · 2015: 31 · 2014: 21 · 2013: 21 · 2012: 24
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, tumor suppressor regulation, MDMX, conserved domains, p53 ubiquitination, proteasomal degradation, cell cycle arrest, apoptosis, oncogenes, cancer therapy
MeSH terms: Amino Acid Sequence, Animals, Gene Expression Regulation, Humans, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Sequence Homology, Amino Acid, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 — master regulator of the p53 tumor suppressor protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks